Jonklaas J, Bianco AC, Bauer AJ, et al
Despite data indicating an increase in both capillarity and lacunarity in the angiotool analysis of HFD SEMA group, these were not statistically significant (Fig
Patients should also inform their healthcare provider if gastrointestinal side effects prevent them from taking other essential medications or if they experience significant weight loss beyond their target, as dose adjustment may be necessary
What works best is consistent, moderate activity with specific timing
In a 104-week trial, once-weekly subcutaneous semaglutide at 2.4 mg led to a mean change in body weight of -15.2% compared to -2.6% with placebo
Many of these errors happen because patients confuse 5 units with 50 units on the syringe